ArticleFrontiers in oncology2026
Glucocorticoids as adjunctive therapy for severe myelosuppression induced by combined immune checkpoint inhibitor and chemotherapy: a case report and literature review.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: We conducted a retrospective case series of two lung cancer patients treated at Suining Central Hospital (January-March 2025) who developed severe myelosuppression after immune checkpoint inhibitor (ICI) -chemotherapy combination therapy, to characterize its clinical characteristics and management. Methods: A retrospective analysis was conducted. Severe myelosuppression (grade IV, CTCAE 5.0) and pancytopenia (trilineage cytopenia) were clearly defined. Immune-related myelosuppression was diagnosed by exclusion of other etiologies. Clinical data and outcomes were analyzed, and a literature review was performed. Results: Both patients with severe myelosuppression after ICI-chemotherapy combination therapy achieved complete hematologic recovery with high-dose glucocorticoids plus standard supportive care. Conclusion: Although chemotherapy is the main cause of myelosuppression, severe myelosuppression following ICI-chemotherapy is multifactorial. Clinicians should perform prompt differential diagnosis and consider an immune-related mechanism. Early glucocorticoids are essential if ICI-related toxicity is suspected. As a small retrospective study, further large-scale trials are needed to validate optimal glucocorticoid dosing, duration, and individualized strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.